ClavystBio is a life sciences investor and venture builder established by Temasek in 2022 to accelerate the commercialization of biotech, medtech, and digital health breakthroughs from Singapore. It operates through three pillars—collaborate, venture, and build—investing in early-stage ventures while providing innovation infrastructure like Node 1.
33% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (4 deals in the last 12 months). Their most common stage is series-a (50% of deals). Average disclosed round size is $56.7M (across 9 rounds with reported amounts).
Portfolio
11
Fund Size
—
Top Stage
Series A
Last 12 Mo
3
Team
Jamie WONG
Director, Finance
Yingmin WANG, PhD
Director, MedTech
Yvonne KOH, PhD
Director, Therapeutics
Charles Yiliu ZHANG, PhD
Assistant Vice President, Therapeutics
Cheryl TAN, MD
Assistant Vice President, MedTech
Johnny NG, PhD
Assistant Vice President, Therapeutics
Vincent LAI
Vice President, Cybersecurity & IT
Marcus TAN, PhD
Senior Associate
Ning MAO, PhD
Senior Associate
Anselm TAN
MedTech Lead
Carol CHAN
Executive Assistant and Office Manager
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| RRespiree Pte Ltd | Series A | — | Feb 2026 |
| BBiobot Surgical | Unknown | — | Jan 2026 |
 Cirrus Therapeutics | Seed | $11M | Oct 2025 |
| RRespiree Pte Ltd | Series A | $11.6M | Jul 2025 |
| RRespiree | Series A | $11.6M | Jul 2025 |
 Allay Therapeutics | Series D | $57.5M | Jun 2025 |
 Callio Therapeutics | Series A | $187M | Mar 2025 |
| NNSG BioLabs | Unknown | $14.5M | Jan 2024 |
 Paratus Sciences | Series D | — | Feb 2023 |
 SunBird Bio | Unknown | $14M | — |
| CCalliotx | Series A | $187M | — |
 Automera | Series A | $16M | — |
Top Co-Investors
Last updated: 8 September 2026